NASDAQ:HUMA Humacyte (HUMA) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free HUMA Stock Alerts $3.70 0.00 (0.00%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$3.30▼$3.9050-Day Range$2.87▼$4.8452-Week Range$1.96▼$5.60Volume2.62 million shsAverage Volume1.11 million shsMarket Capitalization$440.61 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Humacyte alerts: Email Address Humacyte MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside116.2% Upside$8.00 Price TargetShort InterestBearish4.62% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.10Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.90) to ($0.66) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.28 out of 5 starsMedical Sector541st out of 909 stocksBiological Products, Except Diagnostic Industry88th out of 154 stocks 3.4 Analyst's Opinion Consensus RatingHumacyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageHumacyte has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.62% of the float of Humacyte has been sold short.Short Interest Ratio / Days to CoverHumacyte has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Humacyte has recently increased by 5.29%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldHumacyte does not currently pay a dividend.Dividend GrowthHumacyte does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HUMA. Previous Next 2.8 News and Social Media Coverage News SentimentHumacyte has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Humacyte this week, compared to 2 articles on an average week.Search Interest13 people have searched for HUMA on MarketBeat in the last 30 days. This is an increase of 8% compared to the previous 30 days.MarketBeat Follows11 people have added Humacyte to their MarketBeat watchlist in the last 30 days. This is an increase of 10% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Humacyte insiders have not sold or bought any company stock.Percentage Held by Insiders23.10% of the stock of Humacyte is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions44.71% of the stock of Humacyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Humacyte are expected to grow in the coming year, from ($0.90) to ($0.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Humacyte is -3.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Humacyte is -3.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHumacyte has a P/B Ratio of 28.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 Media[Shocking] Elon Musk’s Plan To End BanksLeaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030. Click here now to get your copy. About Humacyte Stock (NASDAQ:HUMA)Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Read More HUMA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HUMA Stock News HeadlinesApril 20, 2024 | msn.comA U.S. Senator Just Bought this Tiny Stock – It’s Up 15% TodayApril 18, 2024 | msn.comA U.S. Senator Just Bought this Tiny Stock - It's Up 15% TodayApril 23, 2024 | Crypto 101 Media (Ad)[Shocking] Elon Musk’s Plan To End BanksLeaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030. April 18, 2024 | benzinga.comAlly Financial Reports Upbeat Earnings, Joins Badger Meter, Genuine Parts And Other Big Stocks Moving Higher On ThursdayApril 18, 2024 | msn.comTuberville’s Trading Raises Questions: Senator Sells Put Options, Invests in Small Biotech Tied to Ukraine-Russia ConflictApril 18, 2024 | americanbankingnews.comShort Interest in Humacyte, Inc. (NASDAQ:HUMA) Expands By 5.3%April 17, 2024 | ca.investing.comU.S. Senator Tommy Tuberville Just Reported a Purchase of $HUMA stockApril 15, 2024 | finance.yahoo.comHumacyte, Inc. (HUMA) Interactive Stock Chart - Yahoo FinanceApril 23, 2024 | Crypto 101 Media (Ad)[Shocking] Elon Musk’s Plan To End BanksLeaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030. April 8, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Humacyte (HUMA)March 26, 2024 | globenewswire.comHumacyte to Host Virtual KOL Event “Hemodialysis Access: A Crossroads of Care,” on March 28, 2024March 23, 2024 | markets.businessinsider.comHumacyte’s Strong Outlook: Buy Rating Affirmed Amid Advancements and Market OpportunityMarch 23, 2024 | finance.yahoo.comQ4 2023 Humacyte Inc Earnings CallMarch 22, 2024 | markets.businessinsider.comBuy Rating for Humacyte: Anticipated FDA Approval and Strong Financials Signal Growth PotentialMarch 22, 2024 | investorplace.comHUMA Stock Earnings: Humacyte Meets EPS for Q4 2023March 22, 2024 | msn.comHumacyte GAAP EPS of -$0.24 in-lineMarch 22, 2024 | globenewswire.comHumacyte Fourth Quarter and Year End 2023 Financial Results and Business UpdateMarch 21, 2024 | markets.businessinsider.comWhat Wall Street expects from Humacyte's earningsMarch 18, 2024 | globenewswire.comHumacyte to Present 2023 Fourth Quarter and Year-End Financial Results and Provide Corporate Update on March 22, 2024March 18, 2024 | ca.finance.yahoo.comHUMA Apr 2024 5.000 callMarch 4, 2024 | marketwatch.comHumacyte Shares Rise 10% on Common Stock OfferingMarch 1, 2024 | msn.comWhy Humacyte (HUMA) Shares Are FallingMarch 1, 2024 | globenewswire.comHumacyte, Inc. to Present at the TD Cowen 44th Annual Health Care ConferenceMarch 1, 2024 | msn.comHumacyte stock dips after pricing stock offering to raise $40.2MFebruary 29, 2024 | marketwatch.comHumacyte Shares Drop 19% After Proposed Public Offering NewsFebruary 29, 2024 | globenewswire.comHumacyte, Inc. Announces Pricing of $40.2 Million Public Offering of Common StockFebruary 29, 2024 | globenewswire.comHumacyte, Inc. Announces Proposed Public Offering of Common StockSee More Headlines Receive HUMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Humacyte and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/22/2024Today4/22/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:HUMA CUSIPN/A CIK1818382 Webwww.constellationalpha.com Phone919-313-9633FaxN/AEmployees183Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$15.00 Low Stock Price Target$4.00 Potential Upside/Downside+116.2%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-110,780,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-199.62% Return on Assets-61.45% Debt Debt-to-Equity Ratio1.20 Current Ratio4.52 Quick Ratio4.52 Sales & Book Value Annual Sales$1.57 million Price / Sales280.64 Cash FlowN/A Price / Cash FlowN/A Book Value$0.13 per share Price / Book28.46Miscellaneous Outstanding Shares119,084,000Free Float91,576,000Market Cap$440.61 million OptionableOptionable Beta1.46 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Laura E. Niklason M.D. (Age 61)Ph.D., Founder, President, CEO & Director Comp: $717.85kMr. Dale A. Sander (Age 64)CFO, Chief Corporate Development Officer & Treasurer Comp: $667.45kDr. Shamik J. Parikh M.D. (Age 51)Chief Medical Officer Comp: $514.72kDr. Juliana L. Blum Ph.D.Co-Founder & Executive AdvisorDr. Heather Ledbetter Prichard Ph.D. (Age 46)Chief Operating Officer Comp: $576.44kMs. Sabrina OsborneExecutive Vice President of Business Strategy & PeopleMr. William John Scheessele (Age 52)Chief Commercial Officer Mr. Harold AltersonSenior Vice President of QualityDr. Yang Cao M.D. (Age 58)Ph.D., Chief Regulatory Officer More ExecutivesKey CompetitorsJasper TherapeuticsNASDAQ:JSPRCaribou BiosciencesNASDAQ:CRBUAura BiosciencesNASDAQ:AURATenaya TherapeuticsNASDAQ:TNYAMeiraGTxNASDAQ:MGTXView All CompetitorsInsiders & InstitutionsTower Research Capital LLC TRC Bought 6,504 shares on 2/13/2024Ownership: 0.009%Kovitz Investment Group Partners LLCBought 12,250 shares on 2/7/2024Ownership: 0.012%Victory Capital Management Inc.Bought 10,099 shares on 2/5/2024Ownership: 0.010%Simplex Trading LLCBought 49,200 shares on 2/2/2024Ownership: 0.000%Powell Investment Advisors LLCBought 9,000 shares on 2/1/2024Ownership: 0.020%View All Insider TransactionsView All Institutional Transactions HUMA Stock Analysis - Frequently Asked Questions Should I buy or sell Humacyte stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Humacyte in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" HUMA shares. View HUMA analyst ratings or view top-rated stocks. What is Humacyte's stock price target for 2024? 4 equities research analysts have issued 12 month price objectives for Humacyte's stock. Their HUMA share price targets range from $4.00 to $15.00. On average, they anticipate the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 116.2% from the stock's current price. View analysts price targets for HUMA or view top-rated stocks among Wall Street analysts. How have HUMA shares performed in 2024? Humacyte's stock was trading at $2.84 at the start of the year. Since then, HUMA stock has increased by 30.3% and is now trading at $3.70. View the best growth stocks for 2024 here. Are investors shorting Humacyte? Humacyte saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 3,980,000 shares, an increase of 5.3% from the March 15th total of 3,780,000 shares. Based on an average daily trading volume, of 968,700 shares, the short-interest ratio is presently 4.1 days. Currently, 4.6% of the company's shares are short sold. View Humacyte's Short Interest. When is Humacyte's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our HUMA earnings forecast. How were Humacyte's earnings last quarter? Humacyte, Inc. (NASDAQ:HUMA) posted its quarterly earnings data on Friday, March, 22nd. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.01. During the same period last year, the firm earned ($0.21) EPS. What ETFs hold Humacyte's stock? ETFs with the largest weight of Humacyte (NASDAQ:HUMA) stock in their portfolio include Clough Select Equity ETF (CBSE).Clough Long/Short Equity ETF (CBLS). How do I buy shares of Humacyte? Shares of HUMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:HUMA) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Humacyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
